Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

A decade after bringing Transcatheter Aortic Valve Replacement (TAVR) to Alaska, doctors at Providence Alaska Medical Center ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Counterintuitively, use of cerebral embolic protection failed to reduce the incidence of stroke in the 72 hours following a transcatheter aortic valve replacement or implantation found a late-breaking ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...